Every Form 4 that Royalty Pharma plc (RPRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RPRX filings page.
Royalty Pharma plc (RPRX) EVP & CFO Terrance P. Coyne reported insider stock sales in a Form 4 filing. On 11/24/2025, multiple sales of Class A ordinary shares were executed, including 55,146 shares held indirectly through TPC RP 2021, LLC at a weighted average price of $38.6663 per share and 10,686 shares at a weighted average price of $37.9604 per share. Additional smaller sales were reported through TPC RP EPA1 LLC.
After these transactions, Coyne continues to hold significant indirect stakes, including 669,010 Class A ordinary shares via TPC RP 2021, LLC and 51,634 Class A ordinary shares via TPC RP EPA1 LLC, plus various IRA and spousal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A ordinary shares and 1,807,277 Class E ordinary shares of Royalty Pharma Holdings Ltd, some of which are subject to vesting conditions. All reported sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025.
Royalty Pharma plc executive George W. Lloyd, EVP, Investments & CLO, reported multiple sales of Class A Ordinary Shares of RPRX on 11/19/2025. The transactions, coded as open-market sales, were executed under a Rule 10b5-1 trading plan adopted on August 20, 2025, meaning they followed a pre-set schedule. Shares were sold indirectly through several family-related entities, with weighted average prices generally between about $37.77 and $39.34 per share, and smaller sales from directly held shares.
After the reported sales, Lloyd continues to hold Class A Ordinary Shares through multiple vehicles, as well as limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 7,527,320 Class A Ordinary Shares. He also holds 1,944,471 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, some of which may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of Class A Ordinary Shares of Royalty Pharma plc (RPRX) on 11/17/2025. The transactions, made under a Rule 10b5-1 trading plan adopted on August 8, 2025, included the sale of 65,844 Class A Ordinary Shares by TPC RP 2021, LLC at a weighted average price of $39.3041 per share and 3,750 Class A Ordinary Shares by TPC RP EPA1 LLC at a weighted average price of $39.304 per share.
Following these trades, the filing reports 724,156 Class A Ordinary Shares held indirectly through TPC RP 2021, LLC and 54,760 Class A Ordinary Shares held indirectly through TPC RP EPA1 LLC, along with additional indirect and direct holdings through IRAs, a spouse’s IRA, and personal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and ownership of 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd that may convert into an equivalent number of Class A Ordinary Shares upon vesting.
Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares. On 11/05/2025, he acquired 36,559 shares at $0 (code A) pursuant to Rule 16b-3 in connection with the settlement of Equity Performance Awards.
Following the transaction, his direct beneficial ownership stands at 940,955 shares. He also reports indirect holdings through various entities, including 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust.
Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.
Following this transaction, 58,510 shares were beneficially owned through TPC RP EPA1 LLC. The filing also lists additional holdings in various accounts, including 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC.
Royalty Pharma plc (RPRX) reported an insider transaction on a Form 4. The EVP, Investments & CLO acquired 6,168 Class A Ordinary Shares on 11/05/2025 at $0, an exempt acquisition under Rule 16b-3 tied to the settlement of Equity Performance Awards.
Following the transaction, the reporting person lists beneficial ownership across multiple indirect entities, including GWL 2023 G HoldCo LLC, GWL 2013 NG, LLC, an IRA, GWL 2014 G, LLC, GWL 2020 G, LLC, GWL 2021 G, LLC, and by spouse, as well as 3,000 shares held directly.
Royalty Pharma (RPRX) executive Christopher Hite reported an exempt acquisition of 6,168 Class A Ordinary Shares at $0 on 11/05/2025, in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.
Following the reported transaction, Hite beneficially owns 658,510 shares indirectly through SCH Investment Partners LLC and 70,000 shares directly.
Royalty Pharma (RPRX) Form 4: EVP, Research & Investments Marshall Urist reported two equity acquisitions. On 11/05/2025, he acquired 4,626 Class A Ordinary Shares at $0 in connection with the settlement of Equity Performance Awards. On 11/07/2025, he converted limited partnership interests in RPI US Partners 2019, LP into 160,000 Class A Ordinary Shares at $0 pursuant to an exchange agreement; these shares are held indirectly via Sandy Lamm LLC.
After these transactions, beneficial ownership includes 43,882 shares held directly, 206,667 shares held indirectly via Sandy Lamm LLC, and 19,020 shares held indirectly via an IRA. He also reports 247,412 LP interests remaining, which are exchangeable into Class A shares under the stated terms.